SCHEMBL2779989

SCHEMBL2779989

Clc1ccc(CBr)cc1-c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 2/20 0.49
CYP2A6 P11509 1/20 0.48
TRPA1 O75762 1/20 0.43
ALDH1A1 P00352 1/20 0.43
TSHR P16473 1/20 0.43
HTR1A P08908 6/20 0.41
HTR2B P41595 5/20 0.41
HTR7 P34969 5/20 0.41
HTR2C P28335 4/20 0.41
HTR5A P47898 4/20 0.41
HTR6 P50406 3/20 0.41
MAOB P27338 2/20 0.41
FFAR1 O14842 1/20 0.40
HTR1D P28221 3/20 0.40
HTR1B P28222 3/20 0.40
HTR2A P28223 3/20 0.40
HTR1E P28566 3/20 0.40
HTR3A P46098 1/20 0.40
BACE1 P56817 1/20 0.39
CYP4F2 P78329 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27746382 0.85 TDP1 (0.47) CSNK2A1CYP2A6HTR1AHTR2BHTR7
SCHEMBL17859694 0.85 CSNK2A1 (0.68) CSNK2A1CYP2A6TRPA1ALDH1A1TSHR
SCHEMBL30440667 0.85 CSNK2A1 (0.68) CSNK2A1CYP2A6TRPA1ALDH1A1TSHR
SCHEMBL28999643 0.82 CSNK2A1 (0.50) CSNK2A1CYP2A6TSHRMAOBFFAR1
SCHEMBL1373277 0.82 ALDH1A1 (0.48) CSNK2A1TRPA1ALDH1A1TSHRBACE1
SCHEMBL2780701 0.81 CSNK2A1 (0.73) CSNK2A1CYP2A6MAOBFFAR1BACE1
SCHEMBL15679162 0.81 CSNK2A1 (0.49) CSNK2A1CYP2A6ALDH1A1HTR1AHTR2B
SCHEMBL3464120 0.80 HTR7 (0.61) CSNK2A1CYP2A6ALDH1A1TSHRHTR1A
Hydrochloric Acid SCHEMBL2780404 0.79 CSNK2A1 (0.74) CSNK2A1CYP2A6MAOBFFAR1BACE1
SCHEMBL20187558 0.79 BACE1 (0.49) CSNK2A1CYP2A6ALDH1A1HTR1AHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016340-A1 PHARMACEUTICAL COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2010-01-21 US disclosed
US-20100016340-A1 PHARMACEUTICAL COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2010-01-21 US disclosed
US-20100016340-A1 PHARMACEUTICAL COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2010-01-21 US disclosed
EP-2029592-A1 PHARMACEUTICAL COMPOUNDS Astex Therapeutics Limited (GB) 2009-03-04 EP disclosed
WO-2007125325-A1 PHARMACEUTICAL COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2007-11-08 WO disclosed
WO-2007125325-A1 PHARMACEUTICAL COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2007-11-08 WO disclosed
US-6162918-A Xanthene and acridine derivatives HOFFMANN-LA ROCHE INC. (US) 2000-12-19 US disclosed
US-5969139-A INHIBITORS OF HERPES SIMPLEX VIRUS THYMIDINE KINASE HOFFMANN-LA ROCHE INC. (US) 1999-10-19 US disclosed
EP-0823426-A1 Xanthene and acridine derivatives and their use F. HOFFMANN-LA ROCHE AG (CH) 1998-02-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016340-A1 PHARMACEUTICAL COMPOUNDS PKN2, PKN1, CSNK1A1 CSNK2A1 10/4885CYP2A6 1869/4885TRPA1 2538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.